Neurocrine Biosciences Inc (NBIX): Richard F Pops , director of Neurocrine Biosciences Inc sold 15,000 shares on May 25, 2016. The Insider selling transaction was reported by the company on May 26, 2016 to the Securities and Exchange Commission. The shares were sold at $46.72 per share for a total value of $700,800.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 18, 2016, Christopher Flint Obrien (Chief Medical Officer) sold 25,000 shares at $45.00 per share price.On Apr 13, 2016, Kyle Gano (Chief Business Development Off) sold 41,770 shares at $43.77 per share price.Also, On Feb 4, 2016, Dimitri E. Grigoriadis (Chief Research Officer) sold 1,375 shares at $37.98 per share price.On Feb 4, 2016, Kevin Charles Gorman (President and CEO) sold 3,125 shares at $38.04 per share price.
Shares of Neurocrine Biosciences (NBIX) ended Wednesday, May 25, 2016 session in red amid volatile trading. The shares closed down -2.21 points or -4.53% at $46.56 with 11,42,981 shares getting traded. Post opening the session at $49.06, the shares hit an intraday low of $46.01 and an intraday high of $49.44 and the price vacillated in this range throughout the day. The company has a market cap of $4,035 M and the number of outstanding shares has been calculated to be 8,66,56,029 shares. The 52-week high of Neurocrine Biosciences is $58.46 and the 52-week low is $31.25.
Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.